La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Editas Medicine a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Editas Medicine..

Editas Medicine (NASDAQ:EDIT) Azioni, Catena delle Opzioni

EDITAS MEDICINE INC

Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Inc

News

Press Releases

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

General

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Earnings

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Health Care

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Penny Stocks

Small Cap

Opinion

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

AVAI

EDIT

QURE

VCYT

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Cabaletta Bio

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Crescent Biopharma

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

ETHZilla

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Palisade Bio

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Pyxis Oncology

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

X4 Pharmaceuticals

Exagen

Zura Bio Limited - Class A Ordinary shares

Comments

Editas Medicine

Editas Medicine (EDIT) Opzioni

Editas Medicine (NASDAQ:EDIT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO